Search results for "From Annals of Internal Medicine"
Pioglitazone improved NASH markers in patients with type 2 or prediabetes and NASH
One hundred one patients with prediabetes or type 2 diabetes and biopsy-proven nonalcoholic steatohepatitis (NASH) were prescribed a hypocaloric diet and randomized to 45 mg of pioglitazone per day or placebo for 18 months. After 18 months, pioglitazone was prescribed open label to all patients without histologic resolution of NASH.
https://diabetes.acponline.org/archives/2016/07/15/5.htm
15 Jul 2016
Diabetes drug classes associated with similar outcomes in low-risk patients
A systematic review and network meta-analysis found no differences between treatments for drug-naive patients with type 2 diabetes at low cardiovascular risk, leading the authors to conclude that metformin is justified as a first-line therapy.
https://diabetes.acponline.org/archives/2020/07/10/6.htm
10 Jul 2020
Recent articles address federal diabetes programs, type 1 diabetes care
The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
https://diabetes.acponline.org/archives/2022/03/11/6.htm
11 Mar 2022
Recovery from metabolic syndrome reduces cardiovascular risk, Korean study finds
The large retrospective study found that hypertension was the metabolic syndrome component with the largest associated increase in risk for a major cardiovascular event.
https://diabetes.acponline.org/archives/2019/12/13/7.htm
13 Dec 2019
SGLT-2 revisited: Diabetes management in chronic kidney disease
The latest episode of Annals On Call features host Robert M. Centor, MD, MACP, and two guests discussing management of patients who have both diabetes and chronic kidney disease.
https://diabetes.acponline.org/archives/2021/06/11/10.htm
11 Jun 2021
SGLT-2s reduced risk for heart failure hospitalization compared to GLP-1s
The retrospective, nonrandomized comparison also found that risk for myocardial infarction or stroke differed by whether type 2 diabetes patients had cardiovascular disease at the time they started a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist.
https://diabetes.acponline.org/archives/2021/10/08/6.htm
8 Oct 2021
Drinking wine associated with slightly improved cardiometabolic risk in type 2 diabetes patients
Cholesterol markers improved in patients with type 2 diabetes who were assigned to drink wine, and some patients also saw glycemic benefits, a recent study found.
https://diabetes.acponline.org/archives/2015/11/13/5.htm
13 Nov 2015
Sotagliflozin linked to more days alive, out of hospital in patients with type 2 diabetes recently hospitalized for heart failure
During a median of nine months of follow-up, daily treatment with 200 to 400 mg/d of the experimental drug was associated with about three more days alive and out of the hospital compared to placebo in an industry-funded randomized trial.
https://diabetes.acponline.org/archives/2021/07/09/6.htm
9 Jul 2021
Peripheral neuropathy associated with increased mortality risk, irrespective of diabetes status
Patients with both diabetes and peripheral neuropathy had the highest risk of death during the study's 13-year follow-up, but the next highest rate was in patients with peripheral neuropathy but no diabetes, followed by those with diabetes without peripheral neuropathy.
https://diabetes.acponline.org/archives/2020/12/11/6.htm
11 Dec 2020
Liraglutide affects beta-blockade for preventing variceal bleeding
A case series of 18 patients with cirrhosis indicated that adding a glucagon-like peptide-1 receptor agonist to a beta-blocker was associated with an increase in heart rate.
https://diabetes.acponline.org/archives/2020/06/12/7.htm
12 Jun 2020